Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
https://finance.yahoo.com/news/baudax-bio-initiates-phase-ii-130000290.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.